Format

Send to

Choose Destination
Int J Cancer. 2015 Aug 15;137(4):753-64. doi: 10.1002/ijc.28965. Epub 2014 May 20.

Bisphosphonates in breast cancer.

Author information

1
Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Room 463, Pittsburgh, PA.
2
Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 300 Halket Street, Room 3524, Pittsburgh, PA.

Abstract

Bisphosphonates are osteoclast inhibitors, currently being used in oncology to prevent or delay bone morbidity in cancer. Oral and intravenous formulations of bisphosphonates have been found to be efficacious in preventing skeletal-related events such as bone pain, pathologic fractures, spinal cord compression and hypercalcemia of malignancy, in patients with bone metastatic breast cancer. Bisphosphonates are also used to prevent bone loss associated with anti-estrogen therapy using aromatase inhibitors. In addition to its role in preventing bone resorption, several pre-clinical studies have noted an anti-tumor role as well. Recent research effort has particularly focused on investigating an adjuvant role for bisphosphonates in early breast cancer. Recently, few randomized trials have found a beneficial effect for adjuvant use of the aminobisphosphonate, zoledronate, in older patients who are post-menopausal. This review article will summarize the various clinical studies investigating the role of bisphosphonates in breast cancer.

KEYWORDS:

bisphosphonates; breast cancer; clodronate; pamidronate; pamidronic acid; zoledronate; zoledronic acid

PMID:
24824552
DOI:
10.1002/ijc.28965
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center